(101 days)
The Passeo-18 peripheral dilatation catheter is indicated to dilate stenoral, popliteal and infrapopliteal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
The Passeo-18 peripheral dilatation catheter is intended for dilatation of stenotic segments in peripheral vessels and arteriovenous dialysis fistulae. The dilatation balloon is designed to inflate to a known diameter at a specific inflation pressure consistent with the compliance chart on the label. One radiopaque marker is located at each end of the balloon to facilitate fluoroscopic visualization and positioning of the balloon catheter towards and across the lesion.
The dilatation catheter includes a soft tapered tip to facilitate advancement of the catheter has two Luer-ports at the proximal end. One port (inflation port) serves for connecting an inflation device to inflate/deflate the balloon. The other port enables flushing of the dilatation catheter has a hydrophobic silicone coating on the shaft outer surface and a hydrophobic patchwork coating on the balloon.
The dilatation catheter is compatible wire and introducer sheath sizes according to the recommendations on the label.
The provided text describes a 510(k) premarket notification for the BIOTRONIK Passeo-18 Peripheral Dilatation Catheter, specifically detailing the justification for clearance of additional device size configurations and minor design changes. The document focuses on non-clinical performance testing to demonstrate substantial equivalence to a previously cleared predicate device. It explicitly states that no clinical data was submitted or relied upon for this substantial equivalence determination. Therefore, questions related to human reader performance, multi-reader multi-case studies, or ground truth established by experts/pathology/outcomes data are not applicable to this submission.
Here's an analysis of the acceptance criteria and the study as described:
1. A table of acceptance criteria and the reported device performance
| Test Name | Test Conditions / Specifications (Acceptance Criteria implicitly defined) | Reported Device Performance |
|---|---|---|
| Dimensional Verification | ||
| Visual and Dimensional Inspection | The balloon catheter was visually inspected for defects, printing, coating homogeneity, x-ray marker positioning and adherence to dimensional specs. | Inspectional acceptance criteria were met. |
| Crossing Profile (system profile) | The diameter of the device is measured by passing the device through a ring-hole gauge to verify French size compatibility. | Acceptance criteria for crossing profile were met. Crossing profile is within specs of predicate. |
| Simulated Use Testing | ||
| Simulated Use | Testing is conducted to demonstrate that the balloon catheter can be safely and reliably prepared, delivered, and retracted using the recommended techniques and instructions for use, without damage to the device. | Acceptance criteria were met. Test shows device performs similar to predicate in a simulated use environment. |
| Trackability and Pushability | Test recorded frictional force (N) when tracked over a guide wire in arterial model. | Acceptance criteria were met. Test shows device performs similar to predicate in a simulated use environment. |
| Pullback and reintroduction test | With the balloon in an appropriate sheath, the friction to introduce and pullback the device after inflation to RBP is evaluated. | Pullback and reintroduction was comparable or better than comparator product. Device performs similar to predicate. |
| Balloon Inflation / Deflation Time | Inflation and deflation time are measured with the device placed in an anatomical model. Inflation and deflation times were measured for characterization. | Inflation time was characterized and deflation time was determined to be according to specifications within the instructions for use. |
| Compatibility with Contrast media | Devices were stored for in contrast medium (ionic and non-ionic) for a specified time, dilated to RBP and then visually inspected. | No visible damage or deformation. Device performs similar to predicate. |
| Mechanical Testing | ||
| Balloon Compliance Radial | Radial compliance is calculated as the balloon diameter at NP and at RBP. | Radial compliance meets acceptance criteria. Device performs similar to predicate. |
| Balloon Compliance Axial | Axial compliance (balloon length at RBP and NP) of the device is measured to verify that it meets product specification. | The difference between balloon length at RBP and NP is within specification. |
| Balloon burst strength | This test determines the balloon Rated Burst Pressure (RBP). The balloon is inflated until burst and pressure at burst is recorded. The burst failure mode is recorded. | Balloons met acceptance criteria for lower 99.9% quantile at 95% confidence interval for all sizes. |
| Balloon Fatigue | The balloons were subjected to repeat inflation/deflation cycles to determine survivability of the balloon. Any loss of pressure, whether due to failure of the balloon, shaft or proximal or distal seals, was reported as a test failure. All failure modes were recorded. | Results demonstrate that 90% of the balloons will survive the test with at least 95% confidence. |
| Tensile Strength Catheter | Following simulated use, a tensile strain is applied along the relevant catheter region until the first sign of fracture. The force (Fmax) at first sign of damage is recorded. | Tensile strength performance (Fmax) for distal and proximal balloon sections met performance specifications. |
| Resistance to Kink | Test was performed to determine the minimum bending radius of the catheter shaft at proximal and distal locations. | Measured mean catheter kink radius was well within the acceptance criteria. |
| Torsional rigidity | Test was performed to assess the ability to inflate and deflate the balloon following application of a torsional load. | Device meets acceptance criteria. Device performs similar to predicate. |
| Rotatability | Test was performed to evaluate torque response. The proximal end of the device is rotated until the first rotational movement at the distal end is observed. | Device meets acceptance criteria. Device performs similar to predicate. |
| Post-Dilatation Test | In a simulated arterial model, balloon is positioned within a deployed stent and subjected to multiple inflation/deflation cycles. | All samples withstood all inflation/deflation cycles within the stent without bursting. Device performs similar to predicate. |
| Biocompatibility | ||
| Cytotoxicity | L929 cells are incubated with test article extracts and evaluated for percentage of cell growth inhibition and compared to a control sample (control: cells exposed to extraction medium). | Growth analyses of cells cultured with test article extract showed no cytotoxic effects of the test article. |
| Gas Chromatography – Mass Spectrometry (GC/MS) | The old materials are compared to the new materials. The test articles are extracted in different solvents (polar and non-polar, e.g. purified water, isopropyl alcohol and hexane) and the extracts are analyzed by GC-MS fingerprint analysis. | There are no significant differences between old and new materials. |
| Fourier Transform Infrared Spectroscopy (FT-IR) analysis | Fourier Transform Infrared Spectroscopy (FT-IR) was utilized to compare the chemical composition of the new materials and old materials. The resulting FT-IR spectra were compared. | Materials had greater than 99% correlation according to FT-IR analysis. The new materials are similar to the predicate. |
| Sterilization Validation | ||
| Correction factor and bioburden | Test conducted to determine typical device bioburden prior to sterilization. | Determine bioburden correction factor. Device meets specifications for CFU/device. |
| Test for inhibitors and activators, Pyrogen test | Test conducted to determine device endotoxin levels after manufacturing. | Bacterial endotoxin test results met acceptance criteria. |
| Validation of the Sterilization Success | Test was performed according to determine if sterilization parameters are sufficient for a SAL of 1x10-6. | Testing confirmed SAL of 10-6. The device performs similar to predicate. |
| Residual gas analysis: EO and ECH | Test conducted to determine EO and ECH residuals on the device following two sterilization cycles. | Device meets acceptance criteria. The device performs similar to predicate. |
2. Sample sizes used for the test set and the data provenance
The document does not specify exact sample sizes (N-numbers) for each individual test. It mentions "all sizes" for balloon burst strength and refers to "samples" in other tests. The data provenance is non-clinical bench testing and simulated use environment testing, not clinical data from patients. The location of testing is not explicitly stated, but it would typically be conducted by the manufacturer (BIOTRONIK) or a contracted lab.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable. This was a non-clinical device performance study. Ground truth was established through engineering specifications, material science analysis, and physical measurements, not by human experts interpreting clinical data.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. Adjudication methods are relevant for studies involving human interpretation or clinical outcomes. This study focuses on physical and mechanical properties of the device.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. No clinical studies, and specifically no MRMC studies, were performed or submitted. The submission explicitly states: "The determination of substantial equivalency on this subject device does not rely upon the clinical data. There is no clinical data submitted in this application."
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
Not applicable. This is not an AI/algorithm-based device. It is a physical medical device (catheter).
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The ground truth for this submission is based on engineering specifications, material standards, and benchmark performance metrics of the predicate device. For example, for "Balloon burst strength," the ground truth is the specified Rated Burst Pressure (RBP) and accepted failure modes. For "Biocompatibility," the ground truth involves established biological safety standards and comparison to the predicate's material composition.
8. The sample size for the training set
Not applicable. There is no "training set" as this is not an AI/machine learning model.
9. How the ground truth for the training set was established
Not applicable. There is no "training set" for this physical device.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three heads facing to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 8, 2015
BIOTRONIK, Inc. Jon Brumbaugh Vice President, Regulatory Affairs and Compliance 6024 Jean Road Lake Oswego, OR 97035
Re: K151744
Trade/Device Name: Passeo-18 Peripheral Dilatation Catheter Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous catheter Regulatory Class: Class II Product Code: LIT Dated: September 4, 2015 Received: September 9, 2015
Dear Mr. Brumbaugh:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
{1}------------------------------------------------
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kenneth J. Cavanaugh -S
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Appendix 1
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K151744
Device Name
Passeo-18 peripheral dilatation catheter
Indications for Use (Describe)
The Passeo-18 peripheral dilatation catheter is indicated to dilate stenoral, popliteal and infrapopliteal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for BIOTRONIK. The logo consists of the word "BIOTRONIK" in large, bold, dark blue letters. To the left of the word is a square symbol with the letters "BIO" inside. Below the word "BIOTRONIK" is the phrase "excellence for life" in a smaller, lighter blue font.
Passeo-18 Peripheral Dilatation Catheter Special 510(k) Premarket Notification
510(k) Summary
| Name and Address of Sponsor: | BIOTRONIK, Inc.6024 Jean RoadLake Oswego, OR 97035 |
|---|---|
| 510(k) Contact Person and Phone Number: | Jon BrumbaughVice President, Requlatory Affairs and ComplianceBIOTRONIK, Inc.6024 Jean RoadLake Oswego, OR 97035Phone: (888) 345-0374Fax: (503) 635-9936jon.brumbaugh@biotronik.com |
| Date Prepared: | June 24, 2015 |
| Device Name: | |
| Proprietary Name: | Passeo-18 |
| Common Name: | Percutaneous Transluminal Angioplasty (PTA) Catheter |
| Classification: | Class II (21 CFR 870.1250) |
| Classification Name: | Catheter, angioplasty, peripheral, transluminal |
| Product Code: | LIT |
Predicate Device:
| 510(k) # | Device Name | Manufacturer | Date of Clearance | |
|---|---|---|---|---|
| Predicate: | K072765 | Passeo-18 | BIOTRONIK | 12-Dec-2007 |
General Description:
The Passeo-18 peripheral dilatation catheter is intended for dilatation of stenotic segments in peripheral vessels and arteriovenous dialysis fistulae. The dilatation balloon is designed to inflate to a known diameter at a specific inflation pressure consistent with the compliance chart on the label. One radiopaque marker is located at each end of the balloon to facilitate fluoroscopic visualization and positioning of the balloon catheter towards and across the lesion.
The dilatation catheter includes a soft tapered tip to facilitate advancement of the catheter has two Luer-ports at the proximal end. One port (inflation port) serves for connecting an inflation device to inflate/deflate the balloon. The other port enables flushing of the dilatation catheter has a hydrophobic silicone coating on the shaft outer surface and a hydrophobic patchwork coating on the balloon.
The dilatation catheter is compatible wire and introducer sheath sizes according to the recommendations on the label.
Indication for Use:
The Passeo-18 peripheral dilatation catheter is indicated to the femoral, poplited and infrapopliteal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the logo for BIOTRONIK. The logo consists of the letters "BIO" inside of a circle that is divided into four quadrants by a plus sign. To the right of the circle is the word "BIOTRONIK" in large, bold, dark blue letters. Below the word "BIOTRONIK" is the phrase "excellence for life" in a smaller, lighter blue font.
| Sizes | Balloon Length (mm) | 20 | 40 | 60 | 80 | 120 | 150 | 170 | 200 | 220 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Usable Length (cm) | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | 90 | 130 | 150 | |||
| Nominal Balloon Ø (mm) | 2 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |||
| 2.5 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| 3 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| 3.5 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| 4 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| 5 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| 6 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| 7 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
Purpose of Submission:
BIOTRONIK submits this 510(k) for clearance of additional device size configurations for the Passeo-18 including additional balloon lengths up to 220mm, referred to collectively as Passeo-18 LE. Additionally, a minor change affecting the entire product range that includes consolidation to a single balloon catheter design. Other changes previously documented as letters to file are also reported.
Summary of technological characteristics in comparison to Predicate Device:
Testing according to the existing design controls demonstrates that the Passeo-18 LE is comparable to the predicate device. The Passeo-18 catheters are identical to the predicate in terms of indications for use, intended use and principles of operation and fundamental technology. Modifications to technological characteristics do not raise new or different questions of safety and effectiveness.
Additional balloon lengths and balloon diameters have been added to the product line. Catheters will now be constructed using one, consolidated design instead of two separate design variants. Minor changes to the grade of materials for catheter construction and materials for packaging have been included. The substantial equivalence of these modifications are supported by producted according to the existing design controls.
Non-Clinical Performance Testing
| Test Name | Test Conditions / Specifications | Summary Results |
|---|---|---|
| Dimensional Verification | ||
| Visual andDimensionalInspection | The balloon catheter was visually inspected for defects,printing, coating homogeneity, x-ray marker positioningand adherence to dimensional specs. | Inspectional acceptance criteriawere met. |
| Crossing Profile(system profile) | The diameter of the device is measured by passing thedevice through a ring-hole gauge to verify French sizecompatibility. | Acceptance criteria for crossingprofile were met. Crossingprofile is within specs ofpredicate. |
| Simulated Use Testing | ||
| Simulated Use | Testing is conducted to demonstrate that the ballooncatheter can be safely and reliably prepared, delivered,and retracted using the recommended techniques andinstructions for use, without damage to the device. | Acceptance criteria were met.Test shows device performssimilar to predicate in asimulated use environment. |
| Test Name | Test Conditions / Specifications | Summary Results |
| Trackability andPushability | Test recorded frictional force (N) when tracked over aguide wire in arterial model | Acceptance criteria were met.Test shows device performssimilar to predicate in asimulated use environment. |
| Pullback andreintroduction test | With the balloon in an appropriate sheath, the friction tointroduce and pullback the device after inflation to RBP isevaluated. | Pullback and reintroduction wascomparable or better thancomparator product. Deviceperforms similar to predicate. |
| Balloon Inflation /Deflation Time | Inflation and deflation time are measured with the deviceplaced in an anatomical model. Inflation and deflationtimes were measured for characterization. | Inflation time was characterizedand deflation time wasdetermined to be according tospecifications within theinstructions for use. |
| Compatibility withContrast media | Devices were stored for in contrast medium (ionic andnon-ionic) for a specified time, dilated to RBP and thenvisually inspected. | No visible damage ordeformation. Device performssimilar to predicate. |
| Mechanical Testing | ||
| Balloon ComplianceRadial | Radial compliance is calculated as thebetween balloon diameter at NP and at RBP. | Radial compliance meetsacceptance criteria. Deviceperforms similar to predicate |
| Balloon ComplianceAxial | Axial compliance (balloon length at RBP and NP) of thedevice is measured to verify that it meets productspecification. | The difference between balloonlength at RBP and NP is withinspecification. |
| Balloon burststrength | This test determines the balloon Rated Burst Pressure(RBP). The balloon is inflated until burst and pressure atburst is recorded. The burst failure mode is recorded. | Balloons met acceptance criteriafor lower 99.9% quantile at 95%confidence interval for all sizes. |
| Balloon Fatigue | The balloons were subjected to repeat inflation/deflationcycles to determine survivability of the balloon. Any lossof pressure, whether due to failure of the balloon, shaft orproximal or distal seals, was reported as a test failure. Allfailure modes were recorded. | Results demonstrate that 90%of the balloons will survive thetest with at least 95%confidence. |
| Tensile StrengthCatheter | Following simulated use, a tensile strain is applied alongthe relevant catheter region until the first sign of fracture.The force (Fmax) at first sign of damage is recorded. | Tensile strength performance(Fmax) for distal and proximalballoon sections metperformance specifications. |
| Resistance to Kink | Test was performed to determine the minimum bendingradius of the catheter shaft at proximal and distallocations | Measured mean catheter kinkradius was well within theacceptance criteria. |
| Torsional rigidity | Test was performed to assess the ability to inflate anddeflate the balloon following application of a torsionalload. | Device meets acceptancecriteria. Device performs similarto predicate. |
| Rotatability | Test was performed to evaluate torque response. Theproximal end of the device is rotated until the firstrotational movement at the distal end is observed. | Device meets acceptancecriteria. Device performs similarto predicate. |
| Test Name | Test Conditions / Specifications | Summary Results |
| Post-Dilatation Test | In a simulated arterial model, balloon is positioned within a deployed stent and subjected to multiple inflation/deflation cycles. | All samples withstood all inflation/deflation cycles within the stent without bursting. Device performs similar to predicate. |
| Biocompatibility | ||
| Cytotoxicity | L929 cells are incubated with test article extracts and evaluated for percentage of cell growth inhibition and compared to a control sample (control: cells exposed to extraction medium). | Growth analyses of cells cultured with test article extract showed no cytotoxic effects of the test article. |
| GasChromatography –Mass Spectrometry(GC/MS) | The old materials are compared to the new materials.The test articles are extracted in different solvents (polar and non-polar, e.g. purified water, isopropyl alcohol and hexane) and the extracts are analyzed by GC-MS fingerprint analysis. | There are no significant differences between old and new materials |
| Fourier TransformInfraredSpectroscopy(FT-IR) analysis | Fourier Transform Infrared Spectroscopy (FT-IR) was utilized to compare the chemical composition of the new materials and old materials The resulting FT-IR spectra were compared. | Materials had greater than 99% correlation according to FT-IR analysis. The new materials are similar to the predicate. |
| Sterilization Validation | ||
| Correction factorand bioburden | Test conducted to determine typical device bioburden prior to sterilization. | Determine bioburden correction factor. Device meets specifications for CFU/device. |
| Test for inhibitorsand activators,Pyrogen test | Test conducted to determine device endotoxin levels after manufacturing. | Bacterial endotoxin test results met acceptance criteria. |
| Validation of theSterilizationSuccess | Test was performed according to determine if sterilization parameters are sufficient for a SAL of 1x10-6. | Testing confirmed SAL of 10-6.The device performs similar to predicate. |
| Residual gasanalysis: EO andECH | Test conducted to determine EO and ECH residuals on the device following two sterilization cycles. | Device meets acceptance criteria. The device performs similar to predicate. |
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the logo for BIOTRONIK. The logo consists of the BIOTRONIK symbol on the left and the word "BIOTRONIK" in large, bold, dark blue letters on the right. Below the word "BIOTRONIK" is the phrase "excellence for life" in a smaller, lighter blue font.
{6}------------------------------------------------
Image /page/6/Picture/1 description: The image shows the logo for BIOTRONIK. The logo consists of the letters "BIO" inside of a circle with a cross through it, followed by the word "BIOTRONIK" in large, bold, dark blue letters. Below the word "BIOTRONIK" is the phrase "excellence for life" in a smaller, lighter blue font.
Clinical Test Data
The determination of substantial equivalency on this subject device does not rely upon the clinical data. There is no clinical data submitted in this application.
Labeling
The instructions for use and labeling were updated with the relevant new device size information.
Conclusion
Based on the non-clinical performance testing using existing design controls from the predicate, the subject Passeo-18 catheter performs as well as the predicate and is therefore substantially equivalent to the predicate Passeo-18 catheter.
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).